High-salt in addition to high-fat diet may enhance inflammation and fibrosis in liver steatosis induced by oxidative stress and dyslipidemia in mice by Yuzaburo Uetake et al.
Uetake et al. Lipids in Health and Disease  (2015) 14:6 
DOI 10.1186/s12944-015-0002-9RESEARCH Open AccessHigh-salt in addition to high-fat diet may enhance
inflammation and fibrosis in liver steatosis induced
by oxidative stress and dyslipidemia in mice
Yuzaburo Uetake1,2, Hitoshi Ikeda3,4, Rie Irie5, Kazuaki Tejima6, Hiromitsu Matsui1, Sayoko Ogura1,7, Hong Wang1,
ShengYu Mu8, Daigoro Hirohama1, Katsuyuki Ando1, Tatsuya Sawamura9,10, Yutaka Yatomi3, Toshiro Fujita1,8
and Tatsuo Shimosawa1,3*Abstract
Background: It is widely known that salt is an accelerating factor for the progression of metabolic syndrome and
causes cardiovascular diseases, most likely due to its pro-oxidant properties. We hypothesized that excessive salt
intake also facilitates the development of nonalcoholic steatohepatitis (NASH), which is frequently associated with
metabolic syndrome.
Methods: We examined the exacerbating effect of high-salt diet on high-fat diet-induced liver injury in a susceptible
model to oxidative stress, apoE knockout and lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) transgenic
mice.
Results: High-salt diet led to NASH in high-fat diet-fed LOX-1 transgenic/apoE knockout mice without affecting
high-fat diet-induced dyslipidemia or hepatic triglyceride accumulation. Additionally, a high-salt and high-fat diet
stimulated oxidative stress production and inflammatory reaction to a greater extent than did a high-fat diet in
the liver of LOX-1 transgenic/apoE knockout mice.
Conclusions: We demonstrated that high-salt diet exacerbated NASH in high-fat diet-fed LOX-1 transgenic /apoE
knockout mice and that this effect was associated with the stimulation of oxidative and inflammatory processes;
this is the first study to suggest the important role of excessive salt intake in the development of NASH.
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Nonalcoholic fatty liver diseaseBackground
Nonalcoholic steatohepatitis (NASH) has been attracting
attention recently because of its increasing prevalence
and close associations with chronic illnesses, such as dia-
betes, dyslipidemia and obesity, which are the major
components of metabolic syndrome (MetS) [1-6] In
addition, several recent studies have reported that there
is also a close association between NASH and hyperten-
sion [7-9]. Therefore, NASH has been considered to be a
hepatic manifestation of MetS. Importantly, the survival* Correspondence: tshimo-tky@umin.ac.jp
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unless otherwise stated.rate was reduced in NASH patients, who frequently died
from liver-related causes in addition to cardiovascular
events [10]. Because NASH is not a benign disease, it is
considered to be an important health-threatening compo-
nent of MetS [11,12].
In the onset and progression of NASH, cholesterol
plays a major role in development of NASH causing oxi-
dative stress in hepatic tissue [13]. A high-fat diet (HFD)
increases free fatty acids, which induce mitochondrial β
oxidation and the overproduction of free radicals [13],
both of which play an important role in progression of
NASH. In general, patients with NASH tend to consume
excessive saturated fatty acid- and cholesterol-enriched
foods without supplying anti-oxidative nutrients, such as
vitamins E and C; susceptibility to oxidative stress andThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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NASH patients [8]. Given the experimental fact that
vitamin E and C improved liver damage in NASH
[14,15], environmental and intrinsic reactive oxygen spe-
cies (ROS)-increasing stimuli accelerate the onset and
progression of NASH.
Recently several studies have suggested that excessive
salt intake would stimulate ROS production in a variety
of organs including blood vessels [16], kidneys [17],
heart [18] and brain [19] in a model using Dahl salt-
sensitive rats. In addition, a high-salt diet (HSD) has also
shown to increase oxidative stress in kidneys [20] and
arteriolar and venular walls in skeletal muscle in normal
rats [21]. Therefore, we hypothesized that excessive salt
intake, an oxidative stress-inducer, is an accelerator of
the onset and progression of HFD-induced NASH due
to ROS overproduction.
To elucidate our hypothesis, we used HFD-fed lectin-
like oxidized low-density lipoprotein receptor-1 (LOX-1)
transgenic (Tg) and apoE knockout (KO) (TgKO) mice
as a model of MetS [22], which follows a chronic course.
Because LOX-1, a receptor for oxidized low-density
lipoprotein (ox-LDL), which accumulates on the ath-
erosclerotic vasculature, is suggested to cause oxidative
stress-related cell damage [23,24], it is expected that
LOX-1 overexpression may further augment organ
damage by salt-induced ROS overproduction and cause
the progression of NASH. In this study, we examined
the effect of a high-salt and high-fat diet (HS/HFD) and
HFD on liver damage in TgKO mice. In addition, we ex-
amined whether the anti-oxidant 4-hydroxy-2, 2, 6,
6-tetramethyl-piperidine-N-oxyl (tempol) could ameli-
orate liver damage in TgKO mice.Materials and methods
Generation of LOX-1 Tg/apoE KO (TgKO) mice
Targeted LOX-1 gene expression in endothelial cells was
generated as described previously [25]. Heterozygous
LOX-1 Tg mice lines carrying 24 copies of the transgene
were crossbred with homozygous C57BL/6:apoE KO
mice to generate TgKO were developed as described pre-
viously [26] and backcrossed eight times with the C57BL/
6 strain to replace the genetic background. Homozygous
mutation in the apoE gene was confirmed by Southern
blot analysis, as described previously [27].Animals and protocols
The present study was conducted in 8-week-old male
TgKO mice. They were randomly allocated into groups
fed a normal diet (ND) (0.5% salt by weight and 13% fat
for calories), HFD (38% fat), or HS/HFD (7.9% salt-
containing HFD) for 8 weeks. Some of HS/HFD-fed
TgKO mice were treated with an anti-oxidant tempol(Sigma-Aldrich, Mo) (7 mmol/L in drinking water for
8 weeks).
All of the animals received humane care in compliance
with the National Research Council’s criteria outlined in
the “Guide for the Care and Use of Laboratory Animals”
prepared by the US National Academy of Sciences and
published by the US National Institutes of Health. The
protocol was approved by the Ethics Committee on Ani-
mal Research of the University of Tokyo (Permit Num-
ber: P08-051). All surgery was performed under sodium
pentobarbital anesthesia, and all efforts were made to
minimize suffering.Liver histology
For histology, 5-μm-thick paraffin sections of liver tissue
were prepared from the center of each hepatic lobe. Sec-
tions were subsequently stained with hematoxylin and
eosin, Masson’s trichrome, or antibodies against 4-
hydroxynonenal (4HNE) and F4/80, TNF-α, superoxide
dismutase-1 (SOD-1), catalase, glutathione. The disease
severity of NASH was assessed according to the grading/
staging system of Brunt et al. [28] and the nonalcoholic
fatty liver disease (NAFLD) activity score of Kleiner
et al. [29].
To examine ROS production, immunohistochemistry
of 4HNE (anti-4HNE antibody; JaICA, Shizuoka, Japan)
and SOD-1 (anti-SOD-1; sc-11407, Santa Cruz, CA),
catalase (anti- catalase; sc-50508, Santa Cruz, CA), gluta-
thione (anti-glutathione; AB-T01, Advanced Targeting
Systems, CA), were performed. For the detection of in-
flammation, the liver sections were stained for F4/80
(anti-F4/80; sc-59171, Santa Cruz, CA) and TNF-α
(anti-TNF-a; ab-34674, Abcam, Cambridge, UK).
Histological features of the liver were assessed by two
investigators who had no knowledge of the origin of the
slides. NAFLD activity score was evaluated on 5 double-
blinded random images per animal (n = 6–23) from dif-
ferent lobes of liver.Measurement of the biochemical index
The serum total cholesterol level was measured after
8 weeks of diet using ELISA kits (T-Cho H, Wako,
Osaka, Japan). Serum alanine transaminase (ALT) activ-
ities were measured spectrophotometrically using a
commercially available test kit (ALT reagents, Alfresa,
Osaka, Japan). Total hepatic triglycerides were extracted
from freeze-dried samples by chloroform:methanol (2:1).
Triglycerides in hepatic tissue extract were subsequently
determined enzymatically in an auto-analyzer using a
commercial kit (L type Wako triglycerides H, Wako,
Osaka, Japan). As a blood marker for hepatic fibrosis,
serum hyaluronic acid (HA) was also assayed using a com-
mercial kit (Lpia ace HA, IATRON, Tokyo, Japan).
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Western blotting was performed as described previously
[30]. 4HNE, fibronectin and beta-actin were blotted on
the same membrane with corresponding monoclonal
antibody. Primary antibodies are 4HNE (JaICA, Shizuoka,
Japan), fibronectin (sc-71113, Santa Cruz, CA) and β-actin
(A-5316, Sigma-Aldrich, St. Louis, MO). Blots were quan-
tified by Scion image analysis.
Analysis of the mRNA levels of endogenous and
transgenic LOX-1
Total RNA was extracted from liver tissues. For Reverse
Transcription Polymerase Chain Reaction (RT-PCR)
analysis, the cDNA product was synthesized and ampli-
fied by PCR using a commercial kit (Thermoscript RT-
PCR kit, Invitrogen, CA). Thermal cycler conditions
were 35 cycles of 94°C for 40 sec, 60°C for 1 minute,
and 72°C for 1 minute for LOX-1.
Measurement of Nicotinamide Adenine Dinucleotide
Phosphate (NADPH) -induced superoxide production in the
liver
The production of superoxide anions in the liver was
measured using lucigenin chemiluminescence in a mi-
croplate luminometer (LB 9507, Berthold Technologies,
Germany) as described previously [18].
Liver perfusion experiments
Mice were anesthetized with pentobarbital (50 mg/kg),
and the catheter introduced into the portal vein. Livers
were perfused with Krebs-Henseleit bicarbonate buffer
saturated with 95% O2 and 5% CO2 at 5 mL/min for
5 minutes at 37°C. Subsequently, livers were perfused
with Krebs-Henseleit bicarbonate buffer containing
1 mM of H2O2 for 10 minutes and Krebs-Henseleit bi-
carbonate buffer containing 0.05% nitro blue tetrazo-
lium (NBT, Sigma-Aldrich, Mo) for 5 minutes. Then,
the livers were fixed by 10% formalin, embedded in par-
affin, sectioned, and stained with nuclear fast red. The
degree of formazan depositions was evaluated by light
microscopy [31].
Statistical analysis
All of the values are expressed as the mean ± SEM. Com-
parisons among groups were calculated by ANOVA
followed by Dunnett’s method, and probability values
of P < 0.05 were considered to indicate statistical
significance.
Results
RT-PCR analysis of LOX-1 expression in the liver
We confirmed only the expression of LOX-1 transgenes
in the liver using RT-PCR analysis. Transgenic bovine
LOX-1 and endogenous murine LOX-1 mRNA in theliver was detected (Additional file 1: Figure S1). En-
dogenous murine LOX-1 and transgenic bovine LOX-1
had comparable signal intensity for an equal molar level
of LOX-1, as previously reported [24].
Systolic blood pressure
Systolic blood pressure was elevated in both HFD and
HS/HFD groups to the same extent (114.2 ± 0.3 mmHg
and 118.4 ± 3.3 mmHg; P < 0.05, P < 0.05 compared with
ND: 106.1 ± 1.0 mmHg, respectively).
Serum lipids
The serum level of total cholesterol in mice fed ND was
elevated (556 ± 34 mg/dL). Both HFD and HS/HFD sig-
nificantly increased the serum level of total cholesterol
(1042 ± 53 mg/dL and 1239 ± 111 mg/dL; P < 0.001, P <
0.001 compared with ND, respectively). The cholesterol
level between HFD and HS/HFD group were compar-
able (P = 0.10). Thus, salt intake did not affect choles-
terol metabolism.
Fat accumulation in the liver and serum alanine
transaminase
Similar to serum cholesterol level, hepatic triglyceride
(TG) concentrations were comparable between HFD
and HS/HFD groups (Figure 1b). In comparison with
ND group, HS/HFD showed statistically significant dif-
ference (P < 0.05) and HFD tended to increase hepatic
TG concentrations (Figure 1b). It is because the hepatic
TG concentrations varies sample to sample in HFD
group (Figure 1a and b) and statistically there is ten-
dency in higher hepatic TG concentrations compare
with ND group. Moreover, the degree of steatosis did
not correspond with hepatic TG concentrations in HFD
group (Figure 1a and b and Figure 2c and Figure 3a),
which was similar to the former studies [32,33]. ALT
level was higher both in HFD and HS/HFD groups than
ND and there were no additive effect of salt intake (P <
0.05, P < 0.05; Figure 1c).
Serum HA and fibronectin expression in the liver
To examine the progression of fibrosis in steatohepatitis,
we evaluated serum HA values (Figure 2a). Salt loading
increased HA. Similar with HA, salt loading increased fi-
bronectin expression in the liver of HS/HFD group (2.6-
fold) compared to ND group (P < 0.05; Figure 2b).
Evaluation of NASH
Macrovesicular steatosis and pericellular fibrosis in the liver
were only found in mice fed HS/HFD but was not apparent
in the groups fed ND and HFD (Figure 1a and Figure 2c).
It is noteworthy that the most apparent changes for steato-
sis were found in HS/HFD group (Figure 1a and Figure 2c
and Figure 3a). Fibrosis was localized around the central
Figure 2 Evaluation of fibrosis and inflammation in the liver of mice with different dietary treatments. a, Serum hyaluronic acid levels. (n = 6-14/
group) b, Fibronectin protein levels in the whole liver (n = 4/group). c, Histological analysis of fibrotic changes. Representative fibrilar collagen deposition in
the liver, which was evaluated using Masson’s trichrome staining. Fibrotic changes are indicated by blue arrowheads and typical hepatocyte
ballooning are indicated by green arrowheads (original magnification, X100, X400). d, Histological analysis of inflammatory changes.
Representative F4/80 immunohistochemical stainning (original magnification, X400). e, Histological analysis of inflammatory changes.
Representative TNF-α immunohistochemical stainning (original magnification, X400). See abbreviations in the legends of Figure 1. #P < 0.05
compared with mice fed ND. Values are means ± SEM.
Figure 1 Fat accumulation in the liver and liver function in mice with different dietary treatments. a, Representative hepatic histological
findings (HE staining: original magnification, X100, X400). b, The effects of normal diet (ND), high-salt and high-fat diet (HS/HFD), high-fat diet (HFD)
and HS/HFD feeding plus 4-hydroxy-2,2,6,6-tetramethyl-piperidine-N-oxyl (tempol) treatment (HS/HFD Tempol) on hepatic triglyceride concentrations
(n = 4-14/group). c, Serum alanine transaminase (ALT) activities (n = 5-11/group). Values are means ± SEM.
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Figure 3 Evaluation of NASH by NAFLD activity score. a, steatosis grade. b, hepatocyte ballooning grade, and c, inflammatory grade. d, fibrosis
stage. e, NAFLD activity score. Five points or more of NAFLD activity score were evaluated for diagnosis of NASH. Solid lines indicate the border of five
points. n = 6-23/group. See abbreviations in the legends of Figure 1.
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tion. This alteration in mice was compatible to the diagnos-
tic criteria of human NASH. The ballooning of hepatocytes
was found in mice fed HS/HFD (Figure 1a and Figure 2c
and Figure 3b). HFD group showed a slight tendency of the
ballooning of hepatocytes, suggesting that excess salt con-
tributes to the damaging process of the liver. Fibrotic
changes in the liver were apparent only in HS/HFD group
(Figure 1a and Figure 2c and Figure 3d).
We examined inflammation in the liver by evaluating
inflammatory cell recruitment and immunostaining F4/
80 and TNF-α (Figure 2d and e). The liver of HS/HFD
group exhibited active inflammation, and salt aggravated
inflammation in comparison with HFD group (Figure 1a
and Figure 2c, d and e and Figure 3c). Additionally,
NASH assessment was performed on all applicable mice.
As a result, we diagnosed NASH in eight mice from HS/
HFD mice group (n = 23) (35%) (Figure 3e). No other
mice from other groups had NASH.Accumulation of Hepatic ROS in NASH
NADPH oxidase activity in the liver was measured by
the lucigenin chemiluminescence method (Figure 4a).
HFD stimulated NADPH oxidase activity (P < 0.05) and
salt aggravated NADPH oxidase activity (P < 0.001).
Next, to confirm the accumulation of oxidative stress,
we performed immunostaining of 4HNE–adducted pro-
tein in liver sections. Lipid peroxidation was markedly
elevated in HS/HFD group compared with ND or HFD
groups (Figure 4b). We quantified the amount of lipid
peroxidation by Western blot analysis of 4HNE in the
liver. 4HNE was increased by approximately 2.0-fold in
HS/HFD (P < 0.01 compared with ND, respectively), but
only a small increase in 4HNE was observed in HFD
group. Salt loading further increased 4HNE expression
significantly (P < 0.05 compared with HFD, respectively;
Figure 4c).
Moreover, we performed immunostaining of SOD-1,
catalase, glutathione in liver sections to confirm anti-
Figure 4 Hepatic ROS accumulation in the liver of each treated group of mice. a, The NADPH oxidase activity (n = 6-11/group). b, Representative
histological findings with immunohistochemical staining for 4-hydroxynonenal (4-HNE: original magnification, X400). c, 4-HNE protein in the whole liver
(n = 4 for each group). d, Oxygen radical formation in Kupffer cells after H2O2 preconditioning. Formazan depositions are indicated by blue arrowheads.
(nuclear red staining: original magnification, X1000). e, Histological analysis of anti-oxidant enzymes activity. Representative SOD-1 immunohistochemical
stainning (original magnification, X400). f, Histological analysis of anti-oxidant enzymes activity. Representative catalase immunohistochemical
stainning (original magnification, X400). g, Histological analysis of anti-oxidants. Representative glutathione immunohistochemical stainning
(original magnification, X400). See abbreviations in the legends of Figure 1. Values are means ± SEM. *P < 0.001 compared with mice fed ND.
**P < 0.01 compared with mice fed ND.
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The liver of HS/HFD group exhibited diffuse staining of
SOD and catalase in comparison with HFD group. Other-
wise, we could confirm staining only the liver of HS/HFD
group of glutathione.
Production of ROS in sinusoidal cells after H2O2
preconditioning
To elucidate the contribution of sinusoidal cells, we deter-
mined the amount of ROS produced in sinusoidal cells
with H2O2 preconditioning. As a result, H2O2 precondi-
tioning only induced formazan depositions in Kupffer cells
from HS/HFD or HFD group (Figure 4d). Salt loading
showed an additive effect on formazan depositions.
Effects of anti-oxidant, tempol, on NASH in HS/HFD-fed
mice
The present findings suggest that excessive salt intake
could be accelerated the onset and progression of HFD-
induced NASH due to ROS overproduction. To clarify
this hypothesis, we examined the effects of tempol on
liver damage in HS/HFD-fed mice. Tempol did not im-
prove total cholesterol levels in HS/HFD-fed mice
(1020 ± 135 mg/dL). However, the hepatic accumulation
of lipid droplets and triglyceride concentration were
normalized by tempol (Figure 1a and b). Additionally,
tempol restored serum HA values (Figure 2a) and hep-
atic fibronectin expression (Figure 2b). Tempol alsoameliorated steatosis, hepatocyte ballooning, fibrosis,
and inflammation in the liver (Figure 3a, b, c and d). As
a result, NASH was not found in tempol-treated HS/
HFD-fed mice (Figure 3e). Antioxidant effects of tem-
pol were confirmed by the measurement of NADPH
oxidase activity (Figure 4a) and 4HNE expression
(Figure 4b and c) in the liver and oxygen radical formation
in Kupffer cells after H2O2 preconditioning (Figure 4d).
Discussion
This study first confirms that salt loading on HFD may
accelerate induction of NASH. HS/HFD induced signifi-
cant fatty degeneration around the hepatic central veins
associated with fibrotic changes. The deterioration of
fatty metabolism, inflammation, and pericellular fiboro-
sis observed in HS/HFD-fed mice met the criteria of
NASH in human [28,29], and Kleiner scores were signifi-
cantly higher in HS/HFD-fed mice (Figure 3) [29]. These
fibrotic changes were comparable with serum HA level
and fibronectin expression in the liver both of which
were significantly elevated in HS/HFD-fed mice.
In the current model, salt loading accelerated the on-
set and progression of NASH in 8 of 23 mice (35%) in a
short term (8 weeks) (Figure 3e). In the pathological cri-
teria of human NASH, in addition to fatty degeneration
and fibrosis, pericellular hepatocyte ballooning is regarded
as a crucial pathologic finding in diagnosis of NASH in
human. Interestingly, the current study confirmed that
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ation in several samples when salt loading was added in
HFD-fed mice. In this group with salt-overload, histopath-
ologic inflammatory and fibrotic changes were more re-
markable and serum HA and fibronectin levels were
significantly higher (Figure 2a and b) compared to HFD-
fed mice without salt-overload.
Meanwhile, the question is that how salt loading can
affect the induction of NASH. Our results suggested that
the level of oxidative stress was exaggerated when salt
intake was overloaded in HFD-fed mice (Figure 4a, b, c
and d). Systolic blood pressure was elevated in both
HFD and HS/HFD groups to the same extent, but we
confirmed NASH only in HS/HFD group. Therefore, the
present findings suggest that excessive salt intake could
accelerate the onset and progression of ROS-induced
NASH. Hypertension may not be essential to the devel-
opment of NASH. In this study, we measured oxidative
stress by 4HNE and confirmed its origin by liver perfu-
sion experiments (ex vivo) using NBT (Figure 4d). Our
results suggested that Kupffer cells and sinusoidal endo-
thelial cells seemed to produce oxidative stress both in
HS/HFD-fed mice and HFD-fed mice (Figure 4d). Serum
concentrations of lipids were significantly increased both
in HS/HFD- and HFD- mice, and these observations
were compatible with well-known hypothesis that chol-
esterol enhances ROS production [13]. However, the in-
teresting observation in this study was that salt overload
further stimulated ROS production in HS/HFD-fed mice
compared to HFD-fed mice. This result suggests that
salt overload may also induce ROS production and ex-
acerbate ROS-associated damage in liver tissue. More-
over, we have performed immunostaining for SOD and
catalase, anti-oxidant enzyme, and glutathione (anti-oxi-
dants) to confirm the activity of anti-oxidant enzyme
and anti-oxidants. The liver of HS/HFD group exhibited
diffuse staining of SOD and catalase in comparison with
HFD group. Otherwise, we could confirm staining only
the liver of HS/HFD group of glutathione. In the HS/HFD
group, even glutathione were produced, glutathione could
not be erased ROS, and then NASH was developed. These
results suggest that in HS/HFD groups, ROS was not fully
erased by glutathione and residual oxidative stress con-
tributed to induction of NASH. However, correlation of
lipid metabolism and salt intake is not clear.
Another noteworthy result was that tempol, a SOD
mimetic, could reduce the NASH-like histopathologic
changes in the liver in HS/HFD-fed mice. Tempol scav-
enges ROS by NADPH oxidase. It has been reported
that ROS itself can activate NADPH oxidase probably in
the feed-forward loop in the vascular system [34-36],
and in turn, reduction of ROS with a radical scavenger,
tempol, can interrupt NADPH oxidase activity. In the
present study, tempol could restore both NADPHoxidase activity (Figure 4a) and ROS as demonstrated by
4HNE expression (Figure 4b and c) in the liver and oxy-
gen radical formation in Kupffer cells after H2O2 pre-
conditioning (Figure 4d). Because tempol scavenges
only ROS and would not directly affect the activity of
NADPH oxidase, the feed-forward activation mechan-
ism between NADPH and ROS might also present in
the liver [18].
The limitations of this study include that the model
used in this study was highly susceptible to fat-overload
and salt loading was relatively strong. Thus, it remains
difficult to determine how much salt loading increase
the risk of NASH. In addition, the detailed mechanism
of ROS production in salt loading is still unclear, and
further investigation is needed. However, the current re-
sults clearly indicated the possibility that salt overload
may accelerate induction of NASH in mice susceptible
to HFD. Furthermore, our model can offer a better model
of NASH compared to conventional animal models re-
quiring longer-term dietary modifications or several
genetic engineering. This model is characterized with
diet-induced overproduction of oxidative stress and
genetic backgrounds for MetS. Therefore, it could be
used to evaluate the effects both environmental and
genetic predisposition for NASH.
In conclusion, salt overload may accelerate the accu-
mulation of oxidative stress under the condition of HFD
consumption and induce NASH in the liver in a dyslip-
idemia model, LOX-1 Tg and apoE KO mice. Although
further investigation is needed to clarify how much salt
intake affects the ROS production and progression of
chronic liver damage, this study would trigger the ex-
perimental interest whether or not salt intake is import-
ant in progression of liver disease.Additional file
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